Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03893175 · ClinicalTrials.gov registry record · Phase 1

Towards Predicting the Analgesic Response to Ibuprofen Following Third-molar Extraction

A Phase 1 study, sponsored by University of Pennsylvania.

Completed
Registry status
Phase 1
Development phase
86
Enrollment target

NCT03893175: Completed Phase 1 study, sponsored by University of Pennsylvania.

NCT03893175 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 86 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03893175, a Phase 1 study, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
Phase 1
Development phase
86 participants
Enrollment target

Study Summary

This research study will evaluate inter-individual variability in the analgesic response to the non-steroidal anti-inflammatory drug (NSAID) ibuprofen after third molar extraction surgery. It will also investigate demographic, clinical, genetic, and environmental factors that cause this variability.

Interventions

  • DRUG Placebo
  • DRUG Acetaminophen
  • DRUG Ibuprofen
  • DRUG Oxycodone

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2019-05-10
Est. Completion 2022-03-02
Phase Phase 1

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT03893175

The ClinicalTrials.gov registry entry for NCT03893175 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT03893175 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03893175 about?

NCT03893175 is a clinical study titled "Towards Predicting the Analgesic Response to Ibuprofen Following Third-molar Extraction". This research study will evaluate inter-individual variability in the analgesic response to the non-steroidal anti-inflammatory drug (NSAID) ibuprofen after third molar extraction surgery. It will also investigate demographic, clinical, genetic, and environmental factors that cause this variability.

What is the current status of trial NCT03893175?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2019-05-10. Estimated completion is 2022-03-02.

What interventions are being tested in trial NCT03893175?

The interventions under investigation include: Placebo (DRUG), Acetaminophen (DRUG), Ibuprofen (DRUG), Oxycodone (DRUG).

Who is sponsoring clinical trial NCT03893175?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.